Cohance Lifesciences Limited has announced the appointment of Umang Vohra as its new Executive Chairman and Group CEO. This strategic move is set to take effect in May 2026, marking a significant leadership transition for the company.
Umang Vohra, a seasoned leader in the pharmaceutical industry, will assume the role of Executive Chairman on May 1, 2026, and Group CEO on May 20, 2026.
His appointment follows the decision of Vivek Sharma to step down for personal reasons. Sharma will remain as an advisor for 9 months to ensure a smooth transition.
Vohra's extensive experience includes leading Cipla Limited as CEO and Managing Director, where he played a pivotal role in the company's transformation into a global pharmaceutical enterprise.
His expertise in managing large-scale businesses and strategic transformations is expected to drive Cohance Lifesciences' growth.
Cohance Lifesciences is a technology-driven CDMO platform specialising in complex chemistry, ADCs, oligonucleotides, and advanced API development.
With over 400 R&D scientists and partnerships with global pharmaceutical innovators, the company is well-positioned in the global CDMO landscape.
Under Vohra's leadership, Cohance aims to leverage its scientific foundation and expand its capabilities in complex APIs, ADCs, and oligonucleotides. The company's integrated R&D centres and focus on proprietary chemistry will be key drivers in its mission to become a leading technology-driven platform.
Umang Vohra expressed his enthusiasm about joining Cohance, highlighting the platform's potential for long-term value creation.
He emphasised the strength of Cohance's technology offerings and R&D talent as a solid foundation for future growth.
Vivek Sharma acknowledged the achievements of Cohance over the years and expressed confidence in the company's readiness for its next chapter.
He conveyed his best wishes to Vohra and the entire Cohance team.
As of April 27, 2026, at 9:41 AM, Cohance Lifesciences share price on NSE was trading at ₹432.10 up by 19.99% from the previous closing price.
The appointment of Umang Vohra as Executive Chairman and Group CEO marks a significant leadership change for Cohance Lifesciences. With Vohra's extensive experience and strategic vision, the company is poised to strengthen its position in the global CDMO market.
Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: Apr 27, 2026, 10:22 AM IST
Team Angel One
We're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
